View printer-friendly version

Download PDF

Emergent BioSolutions to Present at BIO CEO & Investor Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Jan. 30, 2007–Emergent BioSolutions Inc. (NYSE:EBS) today announced that it will present at the BIO CEO & Investor Conference 2007 in New York. Fuad El-Hibri, president, chief executive officer and chairman of the board of directors of Emergent BioSolutions will provide a company overview and outline future growth opportunities at 1:30 pm EST, Tuesday, February 13, 2007 at the Waldorf Astoria in New York, NY.

A webcast of the presentation will be available both live and by replay. To access both the live and archived webcast, please go to www.emergentbiosolutions.com, click on the “Investors” link and proceed to the “Webcasts & Presentations” section. The archived replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and therapeutics that induce or assist the body’s immune system to prevent or treat disease. The company’s biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company’s commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. More information on the company is available at www.emergentbiosolutions.com.